Barclays PLC increased its position in Innoviva Inc (NASDAQ:INVA) by 63.0% during the third quarter, Holdings Channel.com reports. The firm owned 182,486 shares of the biotechnology company’s stock after buying an additional 70,561 shares during the quarter. Barclays PLC’s holdings in Innoviva were worth $1,924,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of INVA. California State Teachers Retirement System grew its position in Innoviva by 1.2% in the 3rd quarter. California State Teachers Retirement System now owns 99,541 shares of the biotechnology company’s stock valued at $1,049,000 after purchasing an additional 1,189 shares during the period. Redwood Investment Management LLC increased its stake in Innoviva by 42.8% during the 3rd quarter. Redwood Investment Management LLC now owns 100,822 shares of the biotechnology company’s stock valued at $1,063,000 after purchasing an additional 30,200 shares in the last quarter. SG Americas Securities LLC raised its holdings in Innoviva by 32.5% during the third quarter. SG Americas Securities LLC now owns 239,251 shares of the biotechnology company’s stock worth $2,522,000 after buying an additional 58,658 shares during the last quarter. First Trust Advisors LP raised its holdings in Innoviva by 401.8% during the third quarter. First Trust Advisors LP now owns 101,736 shares of the biotechnology company’s stock worth $1,072,000 after buying an additional 81,461 shares during the last quarter. Finally, California Public Employees Retirement System lifted its stake in shares of Innoviva by 14.0% in the third quarter. California Public Employees Retirement System now owns 149,168 shares of the biotechnology company’s stock valued at $1,572,000 after buying an additional 18,374 shares in the last quarter. Institutional investors own 71.70% of the company’s stock.

INVA stock opened at $12.97 on Friday. The firm has a market capitalization of $1.31 billion, a PE ratio of 3.67 and a beta of 1.51. The company has a quick ratio of 110.18, a current ratio of 110.18 and a debt-to-equity ratio of 1.37. Innoviva Inc has a twelve month low of $10.03 and a twelve month high of $20.54. The stock’s 50 day moving average is $12.04 and its 200-day moving average is $12.38.

Innoviva (NASDAQ:INVA) last announced its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $0.36 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.36. The business had revenue of $65.38 million during the quarter. Innoviva had a return on equity of 168.69% and a net margin of 141.80%. On average, equities research analysts anticipate that Innoviva Inc will post 2.03 earnings per share for the current fiscal year.

A number of research analysts have recently issued reports on the stock. TheStreet cut shares of Innoviva from a “b-” rating to a “c+” rating in a report on Thursday, August 8th. Zacks Investment Research upgraded shares of Innoviva from a “hold” rating to a “strong-buy” rating and set a $14.00 target price on the stock in a report on Wednesday, November 6th. BidaskClub raised shares of Innoviva from a “hold” rating to a “buy” rating in a research report on Tuesday. Finally, ValuEngine upgraded Innoviva from a “sell” rating to a “hold” rating in a research note on Friday, November 1st.

About Innoviva

Innoviva, Inc engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a long-acting beta2 agonist (LABA), vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate (FF); ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA and LABA.

Read More: G-20

Want to see what other hedge funds are holding INVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Innoviva Inc (NASDAQ:INVA).

Institutional Ownership by Quarter for Innoviva (NASDAQ:INVA)

Receive News & Ratings for Innoviva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva and related companies with MarketBeat.com's FREE daily email newsletter.